Home > Healthcare > Medical Devices > Diagnostic Devices > hematocrit test devices market
Get a free sample of Hematocrit Test Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hematocrit Test Devices Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The market is witnessing significant growth driven by advancements in non-invasive testing, surging need for integrated wearable health technology, and increased adoption of home care testing, among other factors are boosting the industry growth.
The global hematocrit test devices industry was valued at USD 3.8 billion in 2024 and is projected to grow at a 4.4% CAGR from 2025 to 2034, driven by the increasing prevalence of blood disorders and advancements in point-of-care testing.
The instruments segment generated USD 2.2 billion in revenue in 2024, supported by the consistent demand for reliable hematocrit testing in clinical and diagnostic settings.
The U.S. hematocrit test devices market was valued at USD 1.4 billion in 2024 and is expected to grow at a 3.9% CAGR from 2025 to 2034, driven by the high prevalence of blood disorders requiring regular monitoring.
Key players in the market include MENARINI Group, Abbott, BIO-RAD, Boule, Danaher, Diatron, EKF, Roche, HORIBA Medical, Mindray, NIHON KOHDEN, Nova Biomedical, SENSA CORE, SIEMENS Healthineers, and Sysmex.